临床决定限作为设定检验项目分析性能规范的准则
该研究以生物学变异、分析前变异和分析变异之和构成诊断变异,基于参考变化概念和临床显著差异推导临床可接受的分析性能规范。对尿白蛋白、血浆钠、血浆胰腺淀粉酶和血浆肌酐得出了具体规范值,并指出HbA1c和LDL-C需重复测量才能达到患者监测要求。
要点
- 基于临床显著差异推导的分析性能规范为评估实验室分析性能提供了新工具。
- 尿白蛋白、血浆钠、血浆胰腺淀粉酶和血浆肌酐的临床可接受分析性能规范分别为44.9%、0.6%、22.9%和8.0%。
- HbA1c和LDL-C用于患者监测时需重复测量才能满足推导的分析性能规范。
核心结论
- 基于临床决定限的临床可接受分析性能规范模型是评估实验室分析性能的新工具,其可用性取决于临床显著差异限的相关性、所需统计功效和重复测量的可行性。
研究设计与样本
- 方法学研究,将生物学变异、分析前变异和分析变异之和定义为诊断变异,应用参考变化概念于两次测量间的临床显著差异,公式为CD=z*√2*CVD。
- 从国际指南中获取六种被测量物的临床显著差异,通过从诊断变异方差中减去生物学变异和分析前变异方差计算临床可接受分析性能规范,并应用改良公式考虑统计功效(1-β)和重复测量。
主要发现
- 在z=3、α=2.5%、1-β=85%条件下,获得的临床可接受分析性能规范为:尿白蛋白44.9%,血浆钠0.6%,血浆胰腺淀粉酶22.9%,血浆肌酐8.0%。
- 对于血液HbA1c和血浆低密度脂蛋白胆固醇,需要重复测量才能达到患者监测的临床可接受分析性能规范。
- 推导的临床可接受分析性能规范与基于生物学变异的分析性能规范进行了比较。
关键数值与推荐
- 临床显著差异公式:CD = z*√2* CVD,其中CVD为诊断变异。
- 临床可接受分析性能规范计算:从CVD方差中减去CVI和CVPRE的方差。
- 统计条件:z=3,α=2.5%,1-β=85%。
临床怎么用
- 临床实验室可利用基于临床决定限的临床可接受分析性能规范模型评估分析性能。
- 应用时需考虑临床显著差异限的相关性、所需统计功效以及重复测量的可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The biological (CVI), preanalytical (CVPRE), and analytical variation (CVA) are inherent to clinical laboratory testing and consequently, interpretation of clinical test results. METHODS: The sum of the CVI, CVPRE, and CVA, called diagnostic variation (CVD), was used to derive clinically acceptable analytical performance specifications (CAAPS) for clinical chemistry measurands. The reference change concept was applied to clinically significant differences (CD) between two measurements, with the formula CD = z*√2* CVD. CD for six measurands were sought from international guidelines. The CAAPS were calculated by subtracting variances of CVI and CVPRE from CVD. Modified formulae were applied to consider statistical power (1-β) and repeated measurements. RESULTS: The obtained CAAPS were 44.9% for urine albumin, 0.6% for plasma sodium, 22.9% for plasma pancreatic amylase, and 8.0% for plasma creatinine (z = 3, α = 2.5%, 1-β = 85%). For blood HbA1c and plasma low-density lipoprotein cholesterol, replicate measurements were necessary to reach CAAPS for patient monitoring. The derived CAAPS were compared with analytical performance specifications, APS, based on biological variation. CONCLUSIONS: The CAAPS models pose a new tool for assessing APS in a clinical laboratory. Their usability depends on the relevance of CD limits, required statistical power and the feasibility of repeated measurements.
引用
- Rotgers E, Linko S, Theodorsson E, et al. Clinical decision limits as criteria for setting analytical performance specifications for laboratory tests. Clin Chim Acta. 2023. PMID: 36693582. doi:10.1016/j.cca.2023.117233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。